Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation

Abstract Background and purpose Targeted therapy and immunotherapy have led to dramatic change in the treatment of lung cancer, however, the overall 5-year survival rate of lung cancer patients is still suboptimal. It is important to exploit new potential of molecularly targeted therapies. High-freq...

Full description

Bibliographic Details
Main Authors: Meiling Gong, Yan Li, Xiaoping Ye, Linlin Zhang, Zhifang Wang, Xiaowen Xu, Yejing Shen, Cuixia Zheng
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Cell Communication and Signaling
Subjects:
KEAP1/NRF2
Somatic mutation
NRF2 inhibitor
Lung carcinoma
Targeted therapy
Online Access:http://link.springer.com/article/10.1186/s12964-020-00568-z

Internet

http://link.springer.com/article/10.1186/s12964-020-00568-z

Similar Items